IMMUNOVANT INC IMVT 深 滬
等待開盤 09-05 09:30:00 美东时间
16.12
-0.580
-3.47%
華盛通- 最 高16.7433
- 今 開16.58
- 成交量 188.49万股
- 最 低 16.07
- 昨 收 16.70
- 總市值 27.57亿
- 52周最高 32.10
- 市盈率 靜 --
- 換手率 1.10%
- 52周最低 12.72
- 委 比 38.81%
- 總股本 1.71亿
- 歷史最高 53.75
- 量 比 1.07
- 振 幅 4.03%
- 歷史最低 3.145
- 每 手 1
- 風險率 4.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immunovant Reports Durability And Treatment-Free 6-Month Remission Data; Unveils ~80% Response Rate In Off-Treatment Graves' Disease Study
First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal
09-04 01:00
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Immunovant's batoclimab shows promising results for Graves' disease, with 80% of patients achieving normal thyroid function and 50% remaining off anti-thyroid drugs after six months. Two registrational trials for IMVT-1402 are ongoing, with results expected in 2027. Immunovant will discuss the updates during an investor call on September 3, 2025. These findings may offer a potential disease-modifying therapy for previously uncontrolled patients, ...
09-03 16:57
Leaders Come Together to Advance the Industry at Veeva Summit
Alnylam Pharmaceuticals, BeOne Medicines, Intercept Pharmaceuticals, Merck, Pfizer, and Sanofi among biopharmas sharing strategies that set future direction Veeva to showcase innovations, in...
08-21 19:03
JP Morgan Maintains Overweight on Immunovant, Lowers Price Target to $37
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and lowers the price target from $40 to $37.
08-12 23:44
Immunovant GAAP EPS of -$0.71
Immunovant press release (NASDAQ:IMVT): Q1 GAAP EPS of -$0.71 misses by $0.02. As of June 30, 2025, Immunovant’s cash and cash equivalents totaled approximately $598.9 million, providing runway for an...
08-11 19:21
Immunovant Q1 EPS $(0.71), Inline
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.71) per share which met the analyst consensus estimate. This is a 18.33 percent decrease over losses of $(0.60) per share from the same period last year.
08-11 19:13
A Glimpse of Roivant Sciences's Earnings Potential
Roivant Sciences (NASDAQ:ROIV) is preparing to release its quarterly earnings o...
08-08 22:05
UBS Maintains Neutral on Immunovant, Raises Price Target to $18
UBS analyst Ashwani Verma maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $17 to $18.
07-29 06:18
Roivant Sciences sets $500M stock repurchase program
Roivant Sciences (NASDAQ:ROIV) has set a stock repurchase program to buy back up to $500M of its common shares. The program will be funded with available cash and cash equivalents on hand and does not...
06-25 19:51
Immunovant shares are trading higher following a Q4 EPS beat.
Immunovant shares are trading higher following a Q4 EPS beat.
05-30 02:02
